NF2 Deficient Mesothelioma
1 clinical trials · Condition
◉ Watch NF2 Deficient Mesothelioma
| Record | Firm | Date |
|---|---|---|
| Oral TEAD Inhibitor Targeting the Hippo Pathway in Subjects with Advanced Solid Tumors (NCT05228015) | Ikena Oncology | 2022-01-07 |
Track NF2 Deficient Mesothelioma automatically
Every clearance here is in the API, with alerts when new ones post.